Genome sequencing as a platform for pharmacogenetic genotyping: A pediatric cohort study

npj Genomic Medicine

Volumn 2, Issue 1, 2017, Pages

  Cohn, Iris ^a   Paton, Tara A ^b   Marshall, Christian R ^a,b   Basran, Raveen ^a   Stavropoulos, Dimitri J ^a   Ray, Peter N ^a,b   Monfared, Nasim ^a   Hayeems, Robin Z ^a   Meyn, M Stephen ^a   Bowdin, Sarah ^a   Scherer, Stephen W ^a,b,c   Cohn, Ronald D ^a,b,c   Ito, Shinya ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041410740     PISSN: None     EISSN: 20567944     Source Type: Journal    
DOI: 10.1038/s41525-017-0021-8     Document Type: Article

References (45)

1. Crews, K. R., Hicks, J. K., Pui, C.-H., Relling, M. V. & Evans, W. E. Pharmacogenomics and individualized medicine: Translating science into practice. Clin. Pharmacol. Ther. 92, 467-475 (2012).
2. Zhou, Z. W. et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs 75, 589-631 (2015).
3. Stevens, A. et al. Paediatric perspective on pharmacogenomics. Pharmacogenomics 14, 1889-1905 (2013).
4. Thermo Fisher Scientific Inc., 2016. Available at: http://www.thermofisher.com/ca/ en/home/life-science/pcr/real-time-pcr/real-time-pcr-assays/dme-analysis-usingtaqman. html. Accessed September 14, 2016.
5. Pratt, V. M. et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J. Mol. Diagn. 12, 835-846 (2010).
6. Stavropoulos, D. J. et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genom Med 1, 15012 (2016).
7. Chua, E. W. et al.. Cross-comparison of exome analysis, next-generation sequencing of amplicons, and the iPLEXR ADME PGx panel for pharmacogenomic profiling. Front. Pharmacol. 7 (2016). doi:10.3389/fphar.2016.00001.
8. Yang, W. et al. Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clin. Pharmacol. Ther. 100, 380-388 (2016).
9. Sim, S. C. & Ingelman-Sundberg, M. Update on allele nomenclature for human cytochromes P450 (CYP) and the human cytochrome P450 allele (CYP-Allele) nomenclature database. Methods Mol. Biol. 987, 251-259 (2013).
10. Ramamoorthy, A. et al. Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet. Genomics 20, 451 (2010).
11. Swen, J. J. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
12. Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 19, 20-29 (2016).
13. Fujikura, K., Ingelman-Sundberg, M. & Lauschke, V. M. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genomics 25, 584-594 (2015).
14. Black, J. L., Walker, D. L., O'Kane, D. J. & Harmandayan, M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab. Dispos. 40, 111-119 (2012).
15. Gaedigk, A. et al. CYP2D7.2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11, 43-53 (2010).
16. Twist, G. P. et al. Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. NPJ Genom. Med. 1, 15007, doi:10.1038/npjgenmed.2015.7 (2016).
17. Ross, M. G. et al. Characterizing and measuring bias in sequence data. Genome Biol. 14, R51, doi:10.1186/gb-2013-14-5-r51 (2013).
18. Beoris, M., Wilson, J. A., Garces, J. A. & Lukowiak, A. A. CYP2D6 copy number distribution in the US population. Pharmacogen. Genomics 26, 96 (2016).
19. Yang, Y. et al. Molecular findings among patients referred for clinical wholeexome sequencing. JAMA 312, 1870-1879 (2014).
20. Londin, E. R. et al. Performance of exome sequencing for pharmacogenomics. Per Med. 12, 109-115 (2015).
21. Zhao, M., Wang, Q., Wang, Q., Jia, P. & Zhao, Z. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinformatics 14, 1 (2013).
22. Nam, J. Y. et al. Evaluation of somatic copy number estimation tools for wholeexome sequencing data. Brief Bioinform. 17, 185-192 (2016).
23. Zerhouni, E. A. Clinical research at a crossroads. J. Investig. Med. 54, 171-173 (2006).
24. Kearns, G. L. et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
25. Goh, L. L. et al. Analysis of genetic variation in CYP450 genes for clinical implementation. PLoS ONE 12, e0169233 (2017).
26. PharmGKB (The Pharmacogenomics Knowledgebase). Stanford: Stanford University, https://www.pharmgkb.org/view/dosing-guidelines.do?source=#.
27. Relling, M. V. & Evans, W. E. Pharmacogenomics in the clinic. Nature 526, 343-350 (2015).
28. Sing, C. W., Cheung, C. L. & Wong, I. C. Pharmacogenomics.how close/far are we to practising individualized medicine for children? Br. J. Clin. Pharmacol. 79, 419-428 (2015).
29. Johnson, J. A. et al. Implementing personalized medicine: development of a costeffective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92, 437 (2012).
30. Drmanac, R. et al.. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
31. Carnevali, P. et al. Computational techniques for human genome resequencing using mated gapped reads. J. Comp. Biol. 19, 279-292 (2012).
32. Pratt, V. M. et al. Characterization of 137 genomic DNA reference materials for 28 pharmacogenetic genes: A GeT-RM collaborative project. J. Mol. Diagn. 18, 109-123 (2016).
33. Untergasser, A. et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 40, e115-e115 (2012).
34. Scott, S. A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013).
35. Crews, K. R. et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95, 376-382 (2014).
36. Hicks, J. K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98, 127-134 (2015).
37. Birdwell, K. A. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 98, 19-24 (2015).
38. Hicks, J. K. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402-408 (2013).
39. Relling, M. V. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324-325 (2013).
40. Johnson, J. A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625 (2011).
41. Gaedigk, A. et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
42. Martin, M. A. et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin. Pharmacol. Ther. 95, 499-500 (2014).
43. Muir, A. J. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α.based regimens. Clin. Pharmacol. Ther. 95, 141-146 (2014).
44. Ramsey, L. B. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 96, 423-428 (2014).
45. Amstutz, U. et al. Recommendations for HLA-B∗15: 02 and HLA-A∗31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 55, 496-506 (2014)